Physician profile
Itzhak Nir
NPI 1124015482
$18,644.49
in general payments reported to CMS, 2019-2025
16 companies · $6,826 in 2025
The $6,826 reported for 2025 was more than what 94% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,345 · 2020: $203 · 2021: $245 · 2022: $433 · 2023: $690 · 2024: $1,901 · 2025: $6,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,850 · Food and Beverage: $2,916 · Long Term Medical Supply Or Device Loan: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,850.00 |
| Food and Beverage | $2,915.97 |
| Long Term Medical Supply Or Device Loan | $651.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $8,425.47 | 2019-2022 | |
| Davol INC. | $5,915.00 | 2025 | |
| Tela Bio, INC. | $1,878.18 | 2022-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Integra Lifesciences Corporation | $892.24 | 2020-2025 | Durasorb Monofilament Mesh, Integra, Surgimend |
| Mentor Worldwide LLC | $679.89 | 2023-2025 | Artoura Breast Tissue Expander, Mentor Memorygel Resterilizable Gel Sizer, Mentor Memorygel Breast Implant |
| Tei Biosciences INC | $226.70 | 2019 | |
| Revance Therapeutics, INC. | $219.83 | 2024-2025 | Daxxify |
| Ethicon US, LLC | $121.94 | 2024 | Echelon Endopath, Evarrest, Harmonic |
| Sientra, INC. | $111.35 | 2020-2022 | |
| Abbvie INC. | $62.50 | 2023 | |
| Merz North America, INC. | $41.97 | 2020-2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $21.71 | 2019 | |
| Avanos Medical | $18.98 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $14.61 | 2024 | Exparel |
| Galderma Laboratories, L.P. | $14.12 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Itzhak Nir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.